Dexamethasone promotes breast cancer stem cells in obese and not lean mice

• Main Authors: Stephanie Annett (Author), Orla Willis Fox (Author), Damir Vareslija (Author), Tracy Robson (Author)
• Format: Book
• Published: Wiley, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2052-1707; 10.1002/prp2.923
• Keywords: breast cancer; cancer stem cells; glucocorticoids; obesity; tumour initiating cells; Therapeutics. Pharmacology; RM1-950
• Source: Pharmacology Research & Perspectives, Vol 10, Iss 2, Pp n/a-n/a (2022)

Abstract Obesity is highly prevalent in breast cancer patients and is associated with increased recurrence and breast cancer‐specific mortality. Glucocorticoids (GC) are used as an adjuvant in cancer treatment and are associated with promoting breast cancer metastasis through activation of stemness‐related pathways. Therefore, we utilized the synergetic allograft E0771 breast cancer model to investigate if treatment with GCs had differential effects on promoting cancer stem cells in lean and diet‐induced obese mice. Indeed, both lean mice treated with dexamethasone and obese mice with no treatment had no effect on the ex vivo colony‐forming ability, mammosphere formation, or aldehyde dehydrogenase (ALDH) bright subpopulation. However, treatment of obese mice with dexamethasone resulted in a significant increase in ex vivo colony formation, mammosphere formation, ALDH bright subpopulation, and expression of pluripotency transcription factors. GC transcriptionally regulated genes were not altered in the dexamethasone‐treated groups compared to treatment controls. In summary, these results provide initial evidence that obesity presents a higher risk of GC‐induced cancer stemness via non‐genomic GC signaling which is of potential translational significance.